Trichuris suis ova - Fortress Biotech

Drug Profile

Trichuris suis ova - Fortress Biotech

Alternative Names: CNDO-201; TSO; TSO 2500; TSO 7500

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Iowa Research Foundation
  • Developer Charite of Berlin; Dr Falk Pharma; Fortress Biotech; Hadassah Medical Organization; Icahn School of Medicine at Mount Sinai; National Institutes of Health (USA); University of Wisconsin-Madison
  • Class Eukaryota; Immunotherapies; Probiotics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder; Crohn's disease; Multiple sclerosis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 29 Jul 2016 Immanuel Krankenhaus Berlin terminates phase II TSORA trial in Rheumatoid arthritis (adjunctive therapy) in Germany (EudraCT2011-006344-71)
  • 05 May 2016 Charite University terminates phase II trial in Multiple sclerosis in Germany (EudraCT2009-015319-41)
  • 01 Feb 2016 Hadassah Medical Organization terminates a phase II trial in Autistic disorder in Israel due to lack of significant efficacy (NCT01734941)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top